Vor Biopharma Appoints Jeremy Sokolove As New Chief Medical Officer

(RTTNews) - Biotechnology company Vor Biopharma, Inc. (VOR) announced Monday the appointment of Jeremy Sokolove as Chief Medical Officer. Sokolove brings more than two decades of clinical and translational experience in rheumatology and autoimmune disease research and development to the company's leadership team.

Most recently, Sokolove served as Chief Medical Officer In-Residence at Roivant Sciences. Before that, he was Chief Medical Officer at Odyssey Therapeutics. Earlier, he was Senior Vice President and Head of Clinical Pharmacology and Experimental Medicine at GSK.

Sokolove was previously Head of Immunology Translational Science at AbbVie, directing early-phase clinical programs and building portfolio-wide translational medicine strategy. He began his career on the faculty at Stanford University School of Medicine as a practicing rheumatologist and primary investigator.

Sokolove has practiced extensively as an internist and rheumatologist, treating patients and leading clinical research programs focused on autoimmune and inflammatory disorders.